Loading...
600056
XSHG
Market cap1.85bUSD
Nov 20, Last price  
8.24CNY
1D
-2.37%
1Q
-10.43%
Jan 2017
-39.37%
Name

China Medicine Health Industry Co Ltd

Chart & performance

D1W1MN
XSHG:600056 chart
P/E
26.05
P/S
0.35
EPS
0.32
Vol. 1Y
24.18%
Shs. 5Y
6.96%
Rev. 5Y
-2.13%
Div Yld LY
1.28%
Div Yld TTM
0.91%
Revenues
35.30b
+3.38%
2,703,234,0272,475,160,4413,079,157,1094,790,006,2176,259,530,6257,268,599,93813,550,660,39914,829,508,15517,857,372,63920,570,225,96925,945,711,58730,357,020,67831,006,036,44735,284,824,31439,311,753,47136,234,414,70337,592,649,53238,824,430,50434,148,359,63835,303,937,555
Net income
473m
-11.62%
72,314,548234,853,364162,964,358189,269,048194,938,103269,003,808416,081,999484,832,056550,177,827614,453,647949,689,0081,313,406,6901,544,519,829981,345,8491,310,645,729647,057,068735,601,1591,048,039,150535,467,695473,229,055
CFO
1.43b
+41.82%
113,729,11800968,973,078055,431,846961,254,4260994,844,3011,022,250,3521,004,038,713509,178,805257,80701,559,304,980148,420,9841,645,872,491859,075,4521,005,430,5491,425,879,279
Dividend
Jun 26, 20260.07525 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Meheco Group Co., Ltd. functions as a pharmaceutical company with a presence across both domestic Chinese and international markets. The enterprise's primary operations involve the import and export of various national Chinese medicines and health-related items, as well as the production and commercial distribution of pharmaceutical and wellness solutions. It also oversees a network of retail pharmacies. The company's extensive product catalog includes bulk pharmaceutical chemicals, such as those from antibiotic fermentation and chemical synthesis, along with finished dosage forms like tablets, injections, and capsules. It supplies a broad range of antibiotics and medications specifically formulated for cardiovascular, cerebrovascular, chronic, and diabetic conditions. Additionally, its offerings encompass antiviral and anti-infectious agents, gastrointestinal remedies, non-steroidal anti-inflammatory drugs, anti-allergic treatments, specialized botanical products, Western medicine preparations, traditional Chinese patent medicines, processed herbal ingredients, medical equipment and supplies, biological products and their raw materials, various chemical raw materials, and nutritional and general healthcare products. Furthermore, China Meheco Group Co., Ltd. engages in the cultivation, processing, warehousing, and transportation of medicinal herbs, including prominent examples such as ginseng, licorice, ephedra, rhubarb, rheum officinale, astragalus membranaceus, scutellaria baicalensis, and fennel. The company, established in 1984, is headquartered in Beijing, China.

Key people

Guang Yang
Chairman of the Board · since 2024
Xiaohong Ge
Chief Accounting Officer · since 2023
Jian Zhang
Chief Compliance Officer, General Counsel · since 2022
Peng Zhang
Deputy General Manager · since 2025
Jianxiong Chen
Deputy General Manager · since 2025
Heping Lu
Assistant to General Manager · since 2022
Huibo Zhang
Assistant to General Manager · since 2021
Jinghua Yuan
Secretary of the Board · since 2023
Huidong Hu
General Manager, Director · since 2022
Zhen Pan
Director · since 2025
Chaoyin Tong
Director · since 2021
Xin Yang
Director · since 2025
Zhiyong Li
Independent Director · since 2023
Independent Director · since 2024
Yonghong Yan
Independent Director · since 2023
Xinmin Zhang
Independent Director · since 2022
IPO date
May 15, 1997
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
北京市东城区光明中街18号
东城区, BJ 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT